|
1
|
Matsuo K, Eno ML, Im DD, Rosenshein NB and
Sood AK: Clinical relevance of extent of extreme drug resistance in
epithelial ovarian carcinoma. Gynecol Oncol. 116:61–65. 2010.
View Article : Google Scholar
|
|
2
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for over-coming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parikh A, Lee C, Joseph P, Marchini S,
Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, et al:
microRNA-181a has a critical role in ovarian cancer progression
through the regulation of the epithelial-mesenchymal transition.
Nat Commun. 5:29772014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shah JS, Cole AJ, Dickson KA, Soon P and
Marsh DJ: Investigating the role of long non-coding RNAs in
cisplatin resistance in ovarian cancer. Asia Pac J Clin Oncol.
10:42. 2014.
|
|
6
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suh DH, Kim MK, No JH, Chung HH and Song
YS: Metabolic approaches to overcoming chemoresistance in ovarian
cancer. Ann NY Acad Sci. 1229:53–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Tumor suppressor genes associated with drug resistance in
ovarian cancer (Review). Oncol Rep. 30:3–10. 2013.PubMed/NCBI
|
|
9
|
Richardson A and Kaye SB: Drug resistance
in ovarian cancer: The emerging importance of gene transcription
and spatio-temporal regulation of resistance. Drug Resist Updat.
8:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Oncogenes associated with drug resistance in ovarian cancer. J
Cancer Res Clin Oncol. 141:381–395. 2015. View Article : Google Scholar
|
|
11
|
Kahl CR and Means AR: Regulation of cell
cycle progression by calcium/calmodulin-dependent pathways. Endocr
Rev. 24:719–736. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roderick HL and Cook SJ: Ca2+
signalling checkpoints in cancer: Remodelling Ca2+ for
cancer cell proliferation and survival. Nat Rev Cancer. 8:361–375.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rajewskaya TA, Goncharova SA, Konovalova
NP, Kotelnikova RA and Tatyanenko LV: Effect of drug resistance
modulator, NO donor, on membrane structure and function of
membrane-bound Ca2+-activated Mg2+-dependent
ATPase. Bull Exp Biol Med. 146:200–202. 2008. View Article : Google Scholar
|
|
14
|
Clapham DE, Runnels LW and Strübing C: The
TRP ion channel family. Nat Rev Neurosci. 2:387–396. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nilius B and Szallasi A: Transient
receptor potential channels as drug targets: From the science of
basic research to the art of medicine. Pharmacol Rev. 66:676–814.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ong HL and Ambudkar IS: The dynamic
complexity of the TRPC1 channelosome. Channels (Austin). 5:424–431.
2011. View Article : Google Scholar
|
|
17
|
Selli C, Erac Y and Tosun M: Simultaneous
measurement of cytosolic and mitochondrial calcium levels:
Observations in TRPC1-silenced hepatocellular carcinoma cells. J
Pharmacol Toxicol Methods. 72:29–34. 2015. View Article : Google Scholar
|
|
18
|
He B, Liu F, Ruan J, Li A, Chen J, Li R,
Shen J, Zheng D and Luo R: Silencing TRPC1 expression inhibits
invasion of CNE2 nasopharyngeal tumor cells. Oncol Rep.
27:1548–1554. 2012.PubMed/NCBI
|
|
19
|
Tajeddine N and Gailly P: TRPC1 protein
channel is major regulator of epidermal growth factor receptor
signaling. J Biol Chem. 287:16146–16157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng B, Yuan C, Yang X, Atkin SL and Xu
SZ: TRPC channels and their splice variants are essential for
promoting human ovarian cancer cell proliferation and
tumorigenesis. Curr Cancer Drug Targets. 13:103–116. 2013.
View Article : Google Scholar
|
|
21
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edgar R, Domrachev M and Lash AE: Gene
Expression Omnibus: NCBI gene expression and hybridization array
data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar :
|
|
23
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multi-dimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
25
|
Zuberi K, Franz M, Rodriguez H, Montojo J,
Lopes CT, Bader GD and Morris Q: GeneMANIA prediction server 2013
update. Nucleic Acids Res. 41(W1): W115–W122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuhn M, von Mering C, Campillos M, Jensen
LJ and Bork P: STITCH: Interaction networks of chemicals and
proteins. Nucleic Acids Res. 36(Database): D684–D688. 2008.
View Article : Google Scholar :
|
|
27
|
Kuhn M, Szklarczyk D, Pletscher-Frankild
S, Blicher TH, von Mering C, Jensen LJ and Bork P: STITCH 4:
Integration of protein-chemical interactions with user data.
Nucleic Acids Res. 42(D1): D401–D407. 2014. View Article : Google Scholar
|
|
28
|
de Leeuw N, Dijkhuizen T, Hehir-Kwa JY,
Carter NP, Feuk L, Firth HV, Kuhn RM, Ledbetter DH, Martin CL, van
Ravenswaaij-Arts CM, et al: Diagnostic interpretation of array data
using public databases and internet sources. Hum Mutat. 33:930–940.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk-database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vlachos IS, Kostoulas N, Vergoulis T,
Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD,
Prionidis K, Dalamagas T and Hatzigeorgiou AG: DIANA miRPath v.20:
Investigating the combinatorial effect of microRNAs in pathways.
Nucleic Acids Res. 40(W1): W498–W504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hedditch EL, Gao B, Russell AJ, Lu Y,
Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, et
al; Australian Ovarian Cancer Study Group. ABCA transporter gene
expression and poor outcome in epithelial ovarian cancer. J Natl
Cancer Inst. 106:1062014. View Article : Google Scholar
|
|
32
|
Meng D, Chen Y, Zhao Y, Wang J, Yun D,
Yang S, Chen J, Chen H and Lu D: Expression and prognostic
significance of TCTN1 in human glioblastoma. J Transl Med.
12:2882014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bowen NJ, Walker LD, Matyunina LV, Logani
S, Totten KA, Benigno BB and McDonald JF: Gene expression profiling
supports the hypothesis that human ovarian surface epithelia are
multipotent and capable of serving as ovarian cancer initiating
cells. BMC Med Genomics. 2:712009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li M, Balch C, Montgomery JS, Jeong M,
Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis
of DNA methylation and gene expression reveals specific signaling
pathways associated with platinum resistance in ovarian cancer. BMC
Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peters D, Freund J and Ochs RL:
Genome-wide transcriptional analysis of carboplatin response in
chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer
Ther. 4:1605–1616. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu H, Cao Y, Weng D, Xing H, Song X, Zhou
J, Xu G, Lu Y, Wang S and Ma D: Effect of tumor suppressor gene
PTEN on the resistance to cisplatin in human ovarian cancer cell
lines and related mechanisms. Cancer Lett. 271:260–271. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yan X, Fraser M, Qiu Q and Tsang BK:
Over-expression of PTEN sensitizes human ovarian cancer cells to
cisplatin-induced apoptosis in a p53-dependent manner. Gynecol
Oncol. 102:348–355. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu H, Wang K, Liu W and Hao Q: PTEN
overexpression improves cisplatin-resistance of human ovarian
cancer cells through upregulating KRT10 expression. Biochem Biophys
Res Commun. 444:141–146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang X, Wang X, Song X, Liu C, Shi Y,
Wang Y, Afonja O, Ma C, Chen YH and Zhang L: Programmed cell death
4 enhances chemosensitivity of ovarian cancer cells by activating
death receptor pathway in vitro and in vivo. Cancer Sci.
101:2163–2170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and
SPARC-like protein 1 revealing their associations with drug
resistance in ovarian cancer. Int J Oncol. 42:1305–1316.
2013.PubMed/NCBI
|
|
42
|
Sen T, Sen N, Noordhuis MG, Ravi R, Wu TC,
Ha PK, Sidransky D and Hoque MO: OGDHL is a modifier of
AKT-dependent signaling and NF-κB function. PLoS One. 7:e487702012.
View Article : Google Scholar
|
|
43
|
Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, Li
K, Fang Y, Weng D, Weng Y, et al: Cytoplasmic p21 is a potential
predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer.
11:3992011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Materna V, Surowiak P, Markwitz E,
Spaczynski M, Drag-Zalesinska M, Zabel M and Lage H: Expression of
factors involved in regulation of DNA mismatch repair- and
apoptosis pathways in ovarian cancer patients. Oncol Rep.
17:505–516. 2007.PubMed/NCBI
|
|
45
|
Moorehead RA and Singh G: Influence of the
proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol.
59:337–345. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mahner S, Baasch C, Schwarz J, Hein S,
Wölber L, Jänicke F and Milde-Langosch K: C-Fos expression is a
molecular predictor of progression and survival in epithelial
ovarian carcinoma. Br J Cancer. 99:1269–1275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu YY, Li L, Li DR, Zhang W and Wang Q:
Suppression of WWOX gene by RNA interference reverses platinum
resistance acquired in SKOV3/SB cells. Zhonghua Fu Chan Ke Za Zhi.
43:854–858. 2008.In Chinese. PubMed/NCBI
|
|
48
|
Liu T, Zhao L, Chen W, Li Z, Hou H, Ding L
and Li X: Inactivation of von Hippel-Lindau increases ovarian
cancer cell aggressiveness through the HIF1α/miR-210/VMP1 signaling
pathway. Int J Mol Med. 33:1236–1242. 2014.PubMed/NCBI
|
|
49
|
Hamada H, Hagiwara K, Nakajima T and
Tsuruo T: Phosphorylation of the Mr 170,000 to 180,000 glycoprotein
specific to multidrug-resistant tumor cells: Effects of verapamil,
trifluoperazine, and phorbol esters. Cancer Res. 47:2860–2865.
1987.PubMed/NCBI
|
|
50
|
Zhao BX, Sun YB, Wang SQ, Duan L, Huo QL,
Ren F and Li GF: Grape seed procyanidin reversal of P-glycoprotein
associated multi-drug resistance via down-regulation of NF-κB and
MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One.
8:e710712013. View Article : Google Scholar
|
|
51
|
Lee LF, Haskill JS, Mukaida N, Matsushima
K and Ting JP: Identification of tumor-specific paclitaxel
(Taxol)-responsive regulatory elements in the interleukin-8
promoter. Mol Cell Biol. 17:5097–5105. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Duan Z, Feller AJ, Penson RT, Chabner BA
and Seiden MV: Discovery of differentially expressed genes
associated with paclitaxel resistance using cDNA array technology:
Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic
protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res.
5:3445–3453. 1999.PubMed/NCBI
|
|
53
|
Huang Y, Ju B, Tian J, Liu F, Yu H, Xiao
H, Liu X, Liu W, Yao Z and Hao Q: Ovarian cancer stem cell-specific
gene expression profiling and targeted drug prescreening. Oncol
Rep. 31:1235–1248. 2014.PubMed/NCBI
|
|
54
|
Engelmann BJ, Ryan JJ and Farrell NP:
Antidepressants and platinum drugs. Anticancer Res. 34:509–516.
2014.PubMed/NCBI
|
|
55
|
Lee CS, Kim YJ, Jang ER, Kim W and Myung
SC: Fluoxetine induces apoptosis in ovarian carcinoma cell line
OVCAR-3 through reactive oxygen species-dependent activation of
nuclear factor-kappaB. Basic Clin Pharmacol Toxicol. 106:446–453.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hiss DC, Gabriels GA and Folb PI:
Combination of tunicamycin with anticancer drugs synergistically
enhances their toxicity in multidrug-resistant human ovarian
cystadenocarcinoma cells. Cancer Cell Int. 7:52007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rogan AM, Hamilton TC, Young RC, Klecker
RW Jr and Ozols RF: Reversal of adriamycin resistance by verapamil
in human ovarian cancer. Science. 224:994–996. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ozols RF: Pharmacologic reversal of drug
resistance in ovarian cancer. Semin Oncol. 12(Suppl 4): 7–11.
1985.PubMed/NCBI
|
|
59
|
Gene Ontology consortium. http://www.geneontology.org.
|
|
60
|
Gamberoni G, Storari S and Volinia S:
Finding biological process modifications in cancer tissues by
mining gene expression correlations. BMC Bioinformatics. 7:62006.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lagreid A, Hvidsten TR, Midelfart H,
Komorowski J and Sandvik AK: Predicting gene ontology biological
process from temporal gene expression patterns. Genome Res.
13:965–979. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Medical COREMINE. http://www.coremine.com/medical/.
|
|
63
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Tili E, Michaille JJ, Gandhi V, Plunkett
W, Sampath D and Calin GA: miRNAs and their potential for use
against cancer and other diseases. Future Oncol. 3:521–537. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Brazil DP, Park J and Hemmings BA: PKB
binding proteins. Getting in on the Akt. Cell. 111:293–303. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tang W, Jiang Y, Mu X, Xu L, Cheng W and
Wang X: MiR-135a functions as a tumor suppressor in epithelial
ovarian cancer and regulates HOXA10 expression. Cell Signal.
26:1420–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Matei D, Fang F, Shen C, Schilder J,
Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP: Epigenetic
resensitization to platinum in ovarian cancer. Cancer Res.
72:2197–2205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kim YW, Kim EY, Jeon D, Liu JL, Kim HS,
Choi JW and Ahn WS: Differential microRNA expression signatures and
cell type-specific association with Taxol resistance in ovarian
cancer cells. Drug Des Devel Ther. 8:293–314. 2014.PubMed/NCBI
|
|
70
|
Arafa SA, Zhu Q, Barakat BM, Wani G, Zhao
Q, El-Mahdy MA and Wani AA: Tangeretin sensitizes
cisplatin-resistant human ovarian cancer cells through
downregulation of phosphoinositide 3-kinase/Akt signaling pathway.
Cancer Res. 69:8910–8917. 2009. View Article : Google Scholar
|
|
71
|
Lange TS, Stuckey AR, Robison K, Kim KK,
Singh RK, Raker CA and Brard L: Effect of a vitamin D3
derivative (B3CD) with postulated anti-cancer activity in an
ovarian cancer animal model. Invest New Drugs. 28:543–553. 2010.
View Article : Google Scholar :
|
|
72
|
Jiao JW and Wen F: Tanshinone IIA acts via
p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and
lung-resistance protein in cisplatin-resistant ovarian cancer
cells. Oncol Rep. 25:781–788. 2011.
|
|
73
|
Kumar S, Kumar A, Shah PP, Rai SN,
Panguluri SK and Kakar SS: MicroRNA signature of cis-platin
resistant vs. cisplatin sensitive ovarian cancer cell lines. J
Ovarian Res. 4:172011. View Article : Google Scholar
|
|
74
|
Jin L, Huo Y, Zheng Z, Jiang X and Deng H,
Chen Y, Lian Q, Ge R and Deng H: Down-regulation of Ras-related
protein Rab 5C-dependent endocytosis and glycolysis in
cisplatin-resistant ovarian cancer cell lines. Mol Cell Proteomics.
13:3138–3151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Li J, Zhang Y, Gao Y, Cui Y, Liu H, Li M
and Tian Y: Downregulation of HNF1 homeobox B is associated with
drug resistance in ovarian cancer. Oncol Rep. 32:979–988.
2014.PubMed/NCBI
|
|
76
|
Rosanò L, Cianfrocca R, Tocci P, Spinella
F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG and
Bagnato A: Endothelin A receptor/β-arrestin signaling to the Wnt
pathway renders ovarian cancer cells resistant to chemotherapy.
Cancer Res. 74:7453–7464. 2014. View Article : Google Scholar
|
|
77
|
Ko MA, Zehong G, Virtanen C, Guindi M,
Waddell TK, Keshavjee S, et al: MicroRNA expression profiling of
esophageal cancer before and after induction chemoradiotherapy. Ann
Thorac Surg. 94:1094–1102; discussion 1102–1093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wang FJ, Ding Y, Mao YY, Jing FY, Zhang
ZY, Jiang LF, Guo JF, Sun XJ, Jin MJ and Chen K: Associations
between hsa-miR-603 polymorphism, lifestyle-related factors and
colorectal cancer risk. Cancer Biomark. 14:225–231. 2014.PubMed/NCBI
|
|
79
|
Rogler A, Hoja S, Socher E, Nolte E, Wach
S, Wieland W, Hofstädter F, Goebell PJ, Wullich B, Hartmann A, et
al: Role of two single nucleotide polymorphisms in secreted
frizzled related protein 1 and bladder cancer risk. Int J Clin Exp
Pathol. 6:1984–1998. 2013.PubMed/NCBI
|
|
80
|
Zhang J, Zhang T, Ti X, Shi J, Wu C, Ren X
and Yin H: Curcumin promotes apoptosis in A549/DDP
multidrug-resistant human lung adenocarcinoma cells through an
miRNA signaling pathway. Biochem Biophys Res Commun. 399:1–6. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar
|
|
82
|
Della Vittoria Scarpati G, Falcetta F,
Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK,
D'Incalci M, De Placido S and Pepe S: A specific miRNA signature
correlates with complete pathological response to neoadjuvant
chemoradiotherapy in locally advanced rectal cancer. Int J Radiat
Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar
|
|
83
|
Tang J, Tao ZH, Wen D, Wan JL, Liu DL,
Zhang S, Cui JF, Sun HC, Wang L, Zhou J, et al: MiR-612 suppresses
the stemness of liver cancer via Wnt/β-catenin signaling. Biochem
Biophys Res Commun. 447:210–215. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yang Y, Li H, Hou S, Hu B, Liu J and Wang
J: The noncoding RNA expression profile and the effect of lncRNA
AK126698 on cisplatin resistance in non-small-cell lung cancer
cell. PLoS One. 8:e653092013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ichikawa T, Sato F, Terasawa K, Tsuchiya
S, Toi M, Tsujimoto G and Shimizu K: Trastuzumab produces
therapeutic actions by upregulating miR-26a and miR-30b in breast
cancer cells. PLoS One. 7:e314222012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Gu YF, Zhang H, Su D, Mo ML, Song P, Zhang
F and Zhang SC: miR-30b and miR-30c expression predicted response
to tyrosine kinase inhibitors as first line treatment in non-small
cell lung cancer. Chin Med J (Engl). 126:4435–4439. 2013.
|
|
87
|
Pichiorri F, Palmieri D, De Luca L,
Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A,
Cascione L, et al: In vivo NCL targeting affects breast cancer
aggressiveness through miRNA regulation. J Exp Med. 210:951–968.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Huang JW, Wang Y, Dhillon KK, Calses P,
Villegas E, Mitchell PS, Tewari M, Kemp CJ and Taniguchi T:
Systematic screen identifies miRNAs that target RAD51 and RAD51D to
enhance chemosensitivity. Mol Cancer Res. 11:1564–1573. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Huang N, Shah PK and Li C: Lessons from a
decade of integrating cancer copy number alterations with gene
expression profiles. Brief Bioinform. 13:305–316. 2012. View Article : Google Scholar :
|
|
90
|
McLendon R, Friedman A, Bigner D, Van Meir
EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N,
Aldape K, et al; Cancer Genome Atlas Research Network.
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar
|
|
91
|
Sharan R, Ulitsky I and Shamir R:
Network-based prediction of protein function. Mol Syst Biol.
3:882007. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Phuong T and Nhung N: Predicting gene
function using similarity learning. BMC Genomics. 14(Suppl 4):
S42013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Janga SC, Díaz-Mejía JJ and
Moreno-Hagelsieb G: Network-based function prediction and
interactomics: The case for metabolic enzymes. Metab Eng. 13:1–10.
2011. View Article : Google Scholar
|
|
94
|
Yu G, Zhu H, Domeniconi C and Guo M:
Integrating multiple networks for protein function prediction. BMC
Syst Biol. 9(Suppl 1): S32015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Downregulation of NEK11 is associated with drug resistance in
ovarian cancer. Int J Oncol. 45:1266–1274. 2014.PubMed/NCBI
|
|
96
|
Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin
F: Upregulation of NEK2 is associated with drug resistance in
ovarian cancer. Oncol Rep. 31:745–754. 2014.
|
|
97
|
Yin F, Liu L, Liu X, Li G, Zheng L, Li D,
Wang Q, Zhang W and Li L: Downregulation of tumor suppressor gene
ribonuclease T2 and gametogenetin binding protein 2 is associated
with drug resistance in ovarian cancer. Oncol Rep. 32:362–372.
2014.PubMed/NCBI
|
|
98
|
Zeng X, Yin F, Liu X, Xu J, Xu Y, Huang J,
Nan Y and Qiu X: Upregulation of E2F transcription factor 3 is
associated with poor prognosis in hepatocellular carcinoma. Oncol
Rep. 31:1139–1146. 2014.PubMed/NCBI
|
|
99
|
Liu J, Wang LY, Yang AJ, Jiang PF and Wang
MC: Up-regulation of SALL4 associated with poor prognosis in
gastric cancer. Hepatogastroenterology. 61:1459–1464.
2014.PubMed/NCBI
|
|
100
|
Jaber N, Dou Z, Lin RZ, Zhang J and Zong
WX: Mammalian PIK3C3/VPS34: The key to autophagic processing in
liver and heart. Autophagy. 8:707–708. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Yang ZJ, Chee CE, Huang S and Sinicrope
FA: The role of autophagy in cancer: Therapeutic implications. Mol
Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Peracchio C, Alabiso O, Valente G and
Isidoro C: Involvement of autophagy in ovarian cancer: A working
hypothesis. J Ovarian Res. 5:222012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wang J and Wu GS: Role of autophagy in
cisplatin resistance in ovarian cancer cells. J Biol Chem.
289:17163–17173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Veldhoen RA, Banman SL, Hemmerling DR,
Odsen R, Simmen T, Simmonds AJ, Underhill DA and Goping IS: The
chemotherapeutic agent paclitaxel inhibits autophagy through two
distinct mechanisms that regulate apoptosis. Oncogene. 32:736–746.
2013. View Article : Google Scholar
|
